Suppression of in fl ammation reduces endothelial microparticles in active systemic lupus erythematosus

To cite: Parker B, AlHusain A, Pemberton P, et al. Ann Rheum Dis 2014;73:1144–1150. ABSTRACT Background In a prospective observational study, we investigated whether patients with active systemic lupus erythematosus (SLE) had higher indices of endothelial damage and dysfunction than healthy controls and whether improved disease control was associated with improvement in these indices. Methods Twenty-seven patients with active SLE (four or more American College of Rheumatology (ACR) criteria) and 22 age-matched controls were assessed. Endothelial microparticles (EMPs; CD31+/annexin V+/CD42b−) were quantified using flow cytometry. Brachial artery flow-mediated dilatation (FMD) was measured using automated edge-tracking software. Twenty-two patients had a second assessment at a median (IQR) of 20 (16, 22) weeks after initiating new immunosuppressive therapy. Results SLE patients had a median (IQR) baseline global British Isles Lupus Assessment Group Disease Activity Index (BILAG-2004) score of 14 (12, 22). CD31+/annexin V+/CD42b− EMPs were higher (157 548/ml (59 906, 272 643) vs 41 025(30 179, 98 082); p=0.003) and endothelial-dependent FMD was lower (1.63% (−1.22, 5.32) vs 5.40% (3.02, 8.57); p=0.05) in SLE patients than controls. CD31+/annexin V+/CD42b− EMPs correlated inversely with FMD (%) (r −0.40; p=0.006). At follow-up, the median (IQR) change in global BILAG2004 score was −11 (−18, −3). CD31+/annexin V +/CD42b− EMP levels were reduced (166 982/ml (59 906, 278 775 vs 55 655(29 475, 188 659; p=0.02) and FMD had improved (0.33% (−2.31, 4.1) vs 3.19% (0.98, 5.09); p=0.1) at the second visit. Conclusions Active SLE is associated with evidence of increased endothelial damage and endothelial dysfunction, which improved with suppression of inflammation. Better control of active inflammatory disease may contribute to improved cardiovascular risk in patients with SLE.

[1]  Thomas P. Lozito,et al.  Endothelial cell microparticles act as centers of matrix metalloproteinsase‐2 (MMP‐2) activation and vascular matrix remodeling , 2012, Journal of cellular physiology.

[2]  C. Johnsen,et al.  Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[3]  A. Mak,et al.  Endothelium-dependent But Not Endothelium-independent Flow-mediated Dilation Is Significantly Reduced in Patients with Systemic Lupus Erythematosus without Vascular Events: A Metaanalysis and Metaregression , 2011, The Journal of Rheumatology.

[4]  M. Tomšič,et al.  Endothelium-dependent and independent dilation capability of peripheral arteries in patients with systemic lupus erythematosus and antiphospholipid syndrome. , 2011, Clinical and experimental rheumatology.

[5]  G. Nickenig,et al.  Circulating CD 31 1 / Annexin V 1 microparticles correlate with cardiovascular outcomes , 2011 .

[6]  D. Luo,et al.  Endothelium-derived microparticles inhibit angiogenesis in the heart and enhance the inhibitory effects of hypercholesterolemia on angiogenesis. , 2011, American journal of physiology. Endocrinology and metabolism.

[7]  A. Rahman,et al.  The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? , 2011, Lupus.

[8]  L. Magder,et al.  Lupus Atherosclerosis Prevention Study (LAPS) , 2010, Annals of the rheumatic diseases.

[9]  J. Kastelein,et al.  Assessment of atherosclerosis: the role of flow-mediated dilatation. , 2010, European heart journal.

[10]  I. Bruce,et al.  Numerical scoring for the BILAG-2004 index , 2010, Rheumatology.

[11]  Manuel Mayr,et al.  Proteomics, Metabolomics, and Immunomics on Microparticles Derived From Human Atherosclerotic Plaques , 2009, Circulation. Cardiovascular genetics.

[12]  R. Andriantsitohaina,et al.  Circulating microparticles from patients with septic shock exert protective role in vascular function. , 2008, American journal of respiratory and critical care medicine.

[13]  A. Shet.  Characterizing blood microparticles: Technical aspects and challenges , 2008, Vascular health and risk management.

[14]  E. Porteri,et al.  Prognostic role of flow-mediated dilatation of the brachial artery in hypertensive patients , 2008, Journal of hypertension.

[15]  A. Mügge,et al.  Circulating endothelial microparticles correlate inversely with endothelial function in patients with ischemic left ventricular dysfunction. , 2008, Journal of cardiac failure.

[16]  A. Tedgui,et al.  Role of microparticles in atherothrombosis , 2008, Journal of internal medicine.

[17]  D. Thijssen,et al.  Importance of Measuring the Time Course of Flow-Mediated Dilatation in Humans , 2008, Hypertension.

[18]  L. Andrade,et al.  Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. , 2007, Rheumatology.

[19]  I. Bruce,et al.  Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. , 2007, Rheumatology.

[20]  G. London,et al.  In Vivo Shear Stress Determines Circulating Levels of Endothelial Microparticles in End-Stage Renal Disease , 2007, Hypertension.

[21]  G. McVeigh,et al.  Subclinical impairment of arterial mechanics in systemic lupus erythematosus identified by arterial waveform analysis , 2007, Rheumatology International.

[22]  D. Giugliano,et al.  Endothelial microparticles correlate with endothelial dysfunction in obese women. , 2006, The Journal of clinical endocrinology and metabolism.

[23]  L. Horstman,et al.  Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. , 2006, The American journal of cardiology.

[24]  Chantal M Boulanger,et al.  Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. , 2005, Journal of the American Society of Nephrology : JASN.

[25]  R. Schein,et al.  Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis , 2005, Critical care medicine.

[26]  I. Bruce,et al.  Systemic Lupus Erythematosus: An Independent Risk Factor for Endothelial Dysfunction in Women , 2004, Circulation.

[27]  D. Mant,et al.  Endothelial and platelet microparticles in vasculitis of the young. , 2004, Arthritis and rheumatism.

[28]  F. Dignat-George,et al.  Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome , 2004, Thrombosis and Haemostasis.

[29]  J. Schwartz,et al.  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. , 2003, The New England journal of medicine.

[30]  I. Bruce,et al.  Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. , 2003, Arthritis and rheumatism.

[31]  L. Horstman,et al.  High levels of circulating endothelial microparticles in patients with acute coronary syndromes. , 2003, American heart journal.

[32]  Richard A. Preston,et al.  Effects of Severe Hypertension on Endothelial and Platelet Microparticles , 2003, Hypertension.

[33]  David M. Herrington,et al.  Erratum: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. A report of the international brachial artery reactivity task force (Journal of American College of Cardiology (2002) 39 (257-265)) , 2002 .

[34]  D. Gladman,et al.  Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.

[35]  M. Abrahamowicz,et al.  Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. , 2001, Arthritis and rheumatism.

[36]  J. Freyssinet,et al.  Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. , 2000, Circulation.

[37]  J. Levy,et al.  Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program , 1998, Diabetes Care.

[38]  R. D'Agostino,et al.  Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. , 1997, American journal of epidemiology.

[39]  D. Celermajer,et al.  Cigarette Smoking Is Associated With Dose‐Related and Potentially Reversible Impairment of Endothelium‐Dependent Dilation in Healthy Young Adults , 1993, Circulation.

[40]  A. Quyyumi,et al.  Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. , 1990, The New England journal of medicine.

[41]  Ryan A. Harris,et al.  Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. , 2011, American journal of physiology. Heart and circulatory physiology.

[42]  A. Simon,et al.  Endothelial microparticles in diseases , 2008, Cell and Tissue Research.

[43]  I. Bruce,et al.  Development and initial validation of an updated version of the British Isles Lupus Assessment Group ’ s disease activity index for patients with systemic lupus erythematosus , 2005 .

[44]  M. Hochberg.  AMERICAN COLLEGE OF RHEUMATOLOGY REVISED CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC LUPUS ERYTHEMATOSUS , 1997 .

[45]  M. Creager,et al.  IMPAIRED ENDOTHELIUMDEPENDENT VASODILATION IN PATIENTS WITH INSULINDEPENDENT DIABETES MELLITUS , 1993 .